ストックスクリーナーアプリを入手
2.59
3.72%
-0.10
前日終値:
$2.69
開ける：
$2.71
24時間の取引高:
1.43M
Relative Volume:
0.38
時価総額：
$555.97M
収益：
$12.87M
当期純損益:
$-114.34M
株価収益率:
-2.9956
EPS:
-0.8646
ネットキャッシュフロー:
$-79.23M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+9.28%
6か月 パフォーマンス:
+70.39%
1年 パフォーマンス:
+15.62%
1日の値動き範囲:
$2.575
$2.72
1週間の範囲:
$2.34
$2.745
52週間の値動き範囲:
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
名前
Taysha Gene Therapies Inc
セクター
電話
(214) 612-0000
住所
3000 PEGASUS PARK DRIVE, DALLAS
TSHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.59 | 687.82M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-11 | 開始されました | BofA Securities | Buy |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-04-09 | 開始されました | Piper Sandler | Overweight |
| 2023-02-01 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-03-09 | 開始されました | Robert W. Baird | Outperform |
| 2022-03-01 | 開始されました | Wells Fargo | Overweight |
| 2022-02-18 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | Guggenheim | Buy |
| 2021-07-16 | 開始されました | Needham | Buy |
| 2021-06-24 | 開始されました | Truist | Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-06-09 | 開始されました | Wedbush | Outperform |
| 2021-06-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 再開されました | Jefferies | Buy |
| 2021-02-24 | 開始されました | William Blair | Outperform |
| 2021-01-05 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-19 | 開始されました | Goldman | Buy |
| 2020-10-19 | 開始されました | Jefferies | Buy |
| 2020-10-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Taysha Gene Therapies Inc (TSHA) 最新ニュース
Can Taysha Gene Therapies Inc. stock recover from recent declineConsistently profitable trades - jammulinksnews.com
What analysts say about Taysha Gene Therapies Inc. stockGame-changing capital returns - Autocar Professional
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
What drives Taysha Gene Therapies Inc. stock priceUnrivaled growth potential - Autocar Professional
Taysha Gene Therapies Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional
Is Taysha Gene Therapies Inc. a good long term investmentHigh-impact investment strategies - jammulinksnews.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts - Defense World
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Why Taysha Gene Therapies Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
What makes Taysha Gene Therapies Inc. stock price move sharplyFree Long-Term Wealth Growth Plan - Newser
How Taysha Gene Therapies Inc. stock performs during market volatilityFree Popular Stock Recommendations - Newser
How did TSHA's Q1 2024 EPS surprise impact short-term traders? - AInvest
Taysha Gene Therapies (NASDAQ:TSHA) Coverage Initiated at Bank of America - Defense World
Biotech Bargains: Finding Gold in the Healthcare Sell-Off - AInvest
Taysha Gene's 5.9% Surge: A Deep Dive into the Unexplained Rally - AInvest
BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating - Investing.com Canada
BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News - GuruFocus
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN
Goldman Sachs Group Inc's Strategic Acquisition in Taysha Gene Therapies Inc - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies (TSHA) Gets a Buy from Wells Fargo - The Globe and Mail
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock - Nasdaq
Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | - GuruFocus
Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | TSHA Stock News - GuruFocus
Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data - MSN
Rhumbline Advisers Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT - Yahoo Finance
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to S&P Biotechnology Select Industry Index - MarketScreener
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):